Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
Marion T. Weigel(Christian-Albrechts-Universität zu Kiel), Lesley‐Ann Martin(Institute of Cancer Research)
Cited by 43
Related Papers
In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells
|BMC Cancer|2010|56
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo
|Breast Cancer Research|2012|33